Cantitate/Preț
Produs

Hormone Therapy and Castration Resistance of Prostate Cancer

Editat de Yoichi Arai, Osamu Ogawa
en Limba Engleză Hardback – 28 mai 2018
This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged.
During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnicvariation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 74898 lei  3-5 săpt.
  Springer Nature Singapore – 25 dec 2018 74898 lei  3-5 săpt.
Hardback (1) 99891 lei  38-44 zile
  Springer Nature Singapore – 28 mai 2018 99891 lei  38-44 zile

Preț: 99891 lei

Preț vechi: 105148 lei
-5% Nou

Puncte Express: 1498

Preț estimativ în valută:
19123 20844$ 16080£

Carte tipărită la comandă

Livrare economică 14-20 decembrie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9789811070129
ISBN-10: 9811070121
Pagini: 350
Ilustrații: VIII, 433 p. 65 illus., 34 illus. in color.
Dimensiuni: 155 x 235 x 25 mm
Greutate: 1 kg
Ediția:1st ed. 2018
Editura: Springer Nature Singapore
Colecția Springer
Locul publicării:Singapore, Singapore

Cuprins

1. Introduction.- 2. Recent trends in hormone therapy for prostate cancer in Japan.- 3. Risk assessment among patients receiving primary ADT.- 4. Patient-derived xenografts for research on hormonal therapy of prostate cancer.- 5. Impact of GnRH antagonist and LHRH agonist on the gonadal axis.- 6. Controversies on complete androgen blockade.- 7. Adrenal androgen in prostate cancer.- 8. Intermittent ADT for prostate cancer.- 9. Pognostic significance of monitoring serum testosterone in primary ADT.- 10. Ethnic variation in clinical outcomes of primary ADT for prostate cancer.- 11. ADT in combination with radical prostatectomy.- 12. ADT in combination with radiation therapy.- 13. ADT as salvage therapy after definitive treatment.- 14. ADT for clinically localised prostate cancer.- 15. Complications of ADT.- 16. Hot flash.- 17. Oseteoporosis and fracture risk.- 18. Metaboplic change.- 19. Bone scan index as a biomarker of bone metastasis.- 20. Genetic polymorphism analysis in predictingprognosis of metastatic prostate cancer.- 21. Local therapy in combination with ADT for metastatic prostate cancer.- 22. Oxidative stress and CRPC.- 23. Alternative antiandrogen therapy for CRPC.- 24. Optimization of sequential AR targeted therapy for CRPC.- 25. Enzalutamide therapy for mCRPC in Japanese men.- 26. Abiraterone acetate therapy for mCRPC in Japanese men.- 27. Role of estramustine phosphate for CRPC.- 28. Steroid therapy for CRPC.- 29. MicroRNA analysis in prostate cancer.- 30. AR splicing variant in prostate cancer.- 31. Detection of CTC in CRPC.- 32. New biomarker for CRPC: Glycobiologic perspective.- 33. Bone-tageted treatment in CRPC management.- 34. Skeletal complications in CRPC patients.- 35. Urological complications in men dying from prostate cancer.- 36. Prediction of optimal docetaxel regimen for patients with mCRPC.- 37. Intermittent chemotherapy with decetaxel for mCRPC.- 38. Chemotherapy with cabazitaxel for mCRPC in Japanese men.- 39. New tageted approach toCRPC.- 40. Molecular basis of neuroendocrine prostate cancer.- 41. Gene therapy for prostate cancer.- 42. Immune therapy for CRPC.- 43. New approach to CRPC using inactivated virus.- 44. Patient-reported outcome in the management of CRPC.

Recenzii

“This is a comprehensive review of the use of androgen deprivation as treatment for men with prostate cancer. … This is a high quality review of the use of ADT in prostate cancer treatment and is a useful resource for any physician or practitioner interested in understanding the use of ADT in men with prostate cancer.” (James R. Mark, Doody's Book Reviews, December 7, 2018)

Notă biografică

Dr. Yoichi Arai,
Professor and Chairman,
Department of Urology,
Tohoku University School of Medicine
 
Dr. Osamu Ogawa,
Professor and Chairman,
Department of Urology,
Kyoto University Graduate School of Medicine

Textul de pe ultima copertă

This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged.
During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnicvariation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.

Caracteristici

Elucidates the current status of hormone therapy for prostate cancer Clarifies the differences between the evidence from Japan and that from Western countries on hormone therapy for prostate cancer Broadens the reader’s understanding of castration-resistant prostate cancer